The GenoCTC (Gencurix, Seoul, Korea) device utilizes microfluidic magnetophoresis and a specialized isolation chip with optimized ferromagnetic wire patterns to enrich circulating tumor cells using anti-human EpCAM beads, targeting mesenchymal–epithelial transition (MET) markers, or anti-human vimentin beads, targeting epithelial–mesenchymal transition (EMT) markers [111]. This evidence concerns the gene VIM and neoplasm.